Deals

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million
ADC / XDCClearideBio Therapeutics

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million

Shanghai MicuRx Pharmaceuticals, Inc. (SHA: 688373) announced that it intends to enter into an MRX‑23 License Agreement and a Platform Technology Cooperation Agreement with ClearideBio Therapeutics AG, a Switzerland‑based biopharmaceutical…

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CPH: NOVO-BNovo Nordisk

Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support

AIAMS: BAI

AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation

BiotechHKG: 2898

Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO

FinanceGE Healthcare

GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment

Show More